Complement Inhibitor Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$560M

Range: $297M - $810M

Total Deal Value

$2.9B

Range: $1.8B - $4.0B

Royalty Rate

13.9% - 23.1%

Tiered up to 27.1%

Dev Milestones

$472M

Range: $302M - $643M

Model Your Deal

Market Analysis

Complement Inhibitor therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 complement inhibitor asset in immunology & autoimmune is $560M, with total deal values reaching $2.9B. Development milestones average $472M, while regulatory milestones contribute $825M.

The immunology & autoimmune complement inhibitor landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for complement inhibitor immunology & autoimmune deals range from 13.9% to 23.1% at the base tier, with tiered escalation reaching 17.9%-27.1% on blockbuster sales. Commercial milestones averaging $1.1B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a complement inhibitor immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 complement inhibitor licensing deals in immunology & autoimmune average $560M in upfront payments, with a range of $297M to $810M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for complement inhibitor immunology & autoimmune transactions?

The median total deal value for Phase 2 complement inhibitor assets in immunology & autoimmune is $2.9B, ranging from $1.8B to $4.0B. This includes development milestones ($472M), regulatory milestones ($825M), and commercial milestones ($1.1B).

What royalty rates are standard for complement inhibitor deals in immunology & autoimmune?

Base royalty rates for complement inhibitor immunology & autoimmune transactions range from 13.9% to 23.1%, with tiered escalations reaching 17.9%-27.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in complement inhibitor immunology & autoimmune deals?

Complement Inhibitor immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($472M) make up the largest share, followed by commercial milestones ($1.1B) and regulatory milestones ($825M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating